Loading...
XHEL
ORNBV
Market cap13bUSD
Aug 03, Last price  
79.25EUR
1D
-2.28%
1Q
13.38%
Jan 2017
87.40%
IPO
474.28%
Name

Orion Oyj

Chart & performance

D1W1MN
XHEL:ORNBV chart
P/E
22.29
P/S
5.90
EPS
3.55
Div yield, %
2.02%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
11.88%
Revenues
1.89b
+22.50%
311,200,000683,600,000710,700,000771,500,000849,900,000917,900,000980,300,0001,006,900,0001,015,300,0001,015,600,0001,073,500,0001,084,700,000977,400,0001,050,900,0001,078,100,0001,041,000,0001,340,700,0001,189,600,0001,542,400,0001,889,500,000
Net income
500m
+51.65%
66,600,000145,400,000136,300,000151,400,000184,700,000209,500,000208,900,000206,200,000211,300,000208,200,000249,000,000226,000,000330,300,000200,400,000219,900,000193,800,000349,500,000216,800,000329,900,000500,300,000
CFO
317m
+7.98%
81,600,000150,900,000144,400,000204,600,000209,100,000198,900,000221,000,000215,200,000296,700,000254,900,000249,100,000228,400,000230,900,000270,800,000299,100,000215,700,000434,400,000119,000,000293,400,000316,800,000
Dividend
Oct 19, 20260.9 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.
URL
https://www.orion.fi/
IPO date
Jul 03, 2006
Employees
3,657
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT